ALSO READDr Reddys Laboratories announces successful USFDA inspection of its API Srikakulam Plant Dr Reddys Laboratories to pay dividend for FY 2017 Dr Reddys Laboratories launches Ezetimibe and Simvastatin Tablets Dr Reddys Laboratories to hold board meeting Dr Reddys Laboratories launches Bivalirudin for Injection
For its Formulations Manufacturing Unit 2 plant in Bachupally, HyderabadDr Reddys Laboratories announced that its wholly owned subsidiary, betapharm Arzneimittel GmbH, Germany received a communication from the Regulatory Authority of Germany (Regierung von Oberbayern) last night, that the GMP compliance certificate in respect of the Company's Formulations Manufacturing Unit 2 plant in Bachupally, Hyderabad is not renewed consequent to the recent inspection of the plant. Pending revocation of the non-compliance notification, the plant will not be able to make any further despatch to the European Union until the next inspection, to be initiated by an invitation from betapharm.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)